PIDOTIMOD IN THE MANAGEMENT OF RECURRENT PHARYNGOTONSILLAR INFECTIONSIN CHILDHOOD

The efficacy and safety of a new synthetic immunostimulant pidotimod 2 -pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 12 1808-62-6) in recurrent infections of the primary airways were assesse d in a group of 416 children with a history of recurrent respiratory i nfection (RRI). This was a double-blind randomized trial of pidotimod vs. placebo, consisting of a treatment period of 60 days and a follow- up period of 3 months. A reduction in the duration and frequency of in fectious episodes in the group of children treated with pidotimod (one 400 mg oral bottle daily) was observed which was statistically differ ent from the placebo group. The protective effect produced by pidotimo d was also confirmed by a series of recordings made over the five-mont h observation period, which showed a significant reduction in the numb er of days of fever, the severity of the signs and symptoms of acute e pisodes, use of antibiotics and antipyretic drugs and absence from sch ool or nursery school. Safety was excellent.